MX349294B - Formulaciones virales liofilizadas. - Google Patents

Formulaciones virales liofilizadas.

Info

Publication number
MX349294B
MX349294B MX2013006169A MX2013006169A MX349294B MX 349294 B MX349294 B MX 349294B MX 2013006169 A MX2013006169 A MX 2013006169A MX 2013006169 A MX2013006169 A MX 2013006169A MX 349294 B MX349294 B MX 349294B
Authority
MX
Mexico
Prior art keywords
formulations
lyophilized viral
viral formulations
lyophilized
storage
Prior art date
Application number
MX2013006169A
Other languages
English (en)
Other versions
MX2013006169A (es
Inventor
C Coffey Matthew
Pavliv Leo
Serl Sarah
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of MX2013006169A publication Critical patent/MX2013006169A/es
Publication of MX349294B publication Critical patent/MX349294B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12251—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se proporcionan formulaciones virales liofilizadas útiles para la estabilización y almacenamiento de virus y métodos para preparar estas formulaciones. Las formulaciones virales liofilizadas descritas en la presente incluyen un virus (por ej., un virus purificado) y una composición no viral incluyendo excipientes. Las formulaciones se pueden usar, por ejemplo, para conservar la infectividad o inmunogenicidad de los virus durante períodos de almacenamiento.
MX2013006169A 2010-12-02 2011-12-02 Formulaciones virales liofilizadas. MX349294B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41902010P 2010-12-02 2010-12-02
PCT/US2011/063037 WO2012075376A2 (en) 2010-12-02 2011-12-02 Lyophilized viral formulations

Publications (2)

Publication Number Publication Date
MX2013006169A MX2013006169A (es) 2013-10-28
MX349294B true MX349294B (es) 2017-07-21

Family

ID=46162458

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006169A MX349294B (es) 2010-12-02 2011-12-02 Formulaciones virales liofilizadas.

Country Status (15)

Country Link
US (2) US9044498B2 (es)
EP (1) EP2646052B1 (es)
JP (3) JP6034797B2 (es)
KR (1) KR102023207B1 (es)
CN (1) CN103269716B (es)
AU (1) AU2011336410B2 (es)
CA (1) CA2819236A1 (es)
DK (1) DK2646052T3 (es)
EA (1) EA201390812A1 (es)
ES (1) ES2630012T3 (es)
IL (1) IL226646B (es)
MX (1) MX349294B (es)
SG (1) SG190419A1 (es)
TW (1) TW201233803A (es)
WO (1) WO2012075376A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2678721C (en) * 2007-03-12 2018-02-13 Oncolytics Biotech Inc. Reoviruses having modified sequences
US9044498B2 (en) 2010-12-02 2015-06-02 Oncolytics Biotech Inc. Lyophilized viral formulations
CA2819246C (en) * 2010-12-02 2023-04-25 Oncolytics Biotech Inc. Liquid viral formulations
ES2822199T3 (es) * 2011-04-29 2021-04-29 Oncolytics Biotech Inc Métodos de purificación de virus usando cromatografía por permeación en gel
US11273127B2 (en) 2014-05-06 2022-03-15 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for thermally stable multi-targeted antigens
GB201513010D0 (en) * 2015-07-23 2015-09-09 Glaxosmithkline Biolog Sa Novel formulation
IL266264B2 (en) * 2016-11-04 2023-11-01 Baxalta Inc Adeno-associated virus formulations
PE20210106A1 (es) * 2017-10-16 2021-01-19 Serum Institute Of India Pvt Ltd Composiciones de vacuna estables que comprenden inter alia un flavivirus recombinante vivo atenuado y proceso para la preparacion de las mismas
WO2020014479A1 (en) 2018-07-11 2020-01-16 Baxalta Incorporated Aav compositions
CN110279693B (zh) * 2019-07-25 2021-06-15 军事科学院军事医学研究院微生物流行病研究所 一种组合物在制备预防和/或治疗发热伴血小板减少综合征病毒的药物中的应用
CN112107678B (zh) * 2020-09-30 2022-11-18 辰欣药业股份有限公司 一种含有胸腺法新的冻干组合物及其制备方法
CN116270500B (zh) * 2021-12-30 2025-05-06 安徽贝金基因科技有限公司 一种高稳定性的溶瘤病毒组合物及其制备方法和其应用

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5626851A (en) 1987-11-30 1997-05-06 The Wistar Institute Of Anatomy And Biology Rotavirus reassortant vaccine
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
DE69029765T2 (de) 1989-07-24 1997-05-15 Bayer Ag Stabilisierung von hochgereinigten Proteinen
DK0713397T3 (da) 1992-03-24 2003-03-31 United Cancer Res Inst Vaccine indeholdende levende virus
AU2088992A (en) * 1992-05-05 1993-11-11 Research Foundation For Microbial Diseases Of Osaka University, The Stabilized live vaccine
CA2158935A1 (en) 1993-10-12 1995-04-20 Chiron Viagene, Inc. Methods for preserving recombinant viruses
BR9507657A (pt) 1994-05-16 1997-09-09 Merck & Co Inc Proteina isolada e purificada de papilomavirus recombinante capsideos particulas semelhantes a virus processos a virus processos para produzir a proteina para tratar ou prevenir a infecçao por papilomavirus para produzir uma proteina de capsideo de papilomavirus recombinante montada em um capsideo ou particula semelhante a virus e para induzir uma resposta imune em um animal vertebrado composiçoes farmacêuticas kit para a detecçao de papilomavirus ou anticorpos para papilomavirus e sistema sinte
WO1996001651A1 (en) 1994-07-11 1996-01-25 The Government Of The United States Of America, Represented By The Department Of Health And Human Services Attenuated human rotavirus vaccine
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6165773A (en) 1995-10-25 2000-12-26 Provalis Uk Limited Methods of preserving viruses
GB9521806D0 (en) 1995-10-25 1996-01-03 Cortecs Ltd Preservation methods
FR2742756B1 (fr) 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
JP4653262B2 (ja) 1996-09-26 2011-03-16 メルク・シャープ・エンド・ドーム・コーポレイション ロタウイルスワクチン製剤類
US5932223A (en) * 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
US6616931B1 (en) 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
US6403098B1 (en) 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6544769B1 (en) 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US20080261289A1 (en) 1996-12-13 2008-10-23 Schering-Plough Corporation Compositions comprising viruses and methods for concentrating virus preparations
US6051238A (en) 1996-12-20 2000-04-18 Merck & Co., Inc. Stabilizers for lyophilized mumps vaccines
WO1998028000A1 (en) 1996-12-20 1998-07-02 Merck & Co., Inc. Stabilizers for lyophilized vaccines
US6290967B1 (en) 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
DK1054955T3 (da) 1998-02-17 2007-01-15 Schering Corp Sammensætninger omfattende vira og fremgangsmåde til at opkoncentrere viruspræparater
GB9808922D0 (en) * 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
WO2000006196A2 (en) 1998-07-28 2000-02-10 The Government Of The United States Of America, Represented By The Department Of Health And Human Services Multivalent human-bovine rotavirus vaccine
CN1062770C (zh) * 1998-11-12 2001-03-07 卫生部长春生物制品研究所 甲肝-麻疹二联疫苗及其生产方法
ES2323991T3 (es) 1998-11-16 2009-07-28 Introgen Therapeutics, Inc. Formulacion de adenovirus para terapia genica.
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
AU4188100A (en) 1999-04-08 2000-11-14 Gregory M. Glenn Dry formulation for transcutaneous immunization
US6592869B2 (en) 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
RU2277905C2 (ru) 1999-08-24 2006-06-20 Тева Фармасьютикал Индастриз, Лтд. Вакцинная композиция и способ ее применения
CN1188111C (zh) 1999-10-29 2005-02-09 耐科塔医药公司 分散性得到改进的干粉组合物
CA2799545A1 (en) 2000-03-07 2001-09-13 Merck Sharp & Dohme Corp. Adenovirus formulations
US7456009B2 (en) * 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
NZ552576A (en) 2000-06-08 2008-06-30 Powderject Vaccines Inc Salt adjuvant-containing gel-forming free flowing compositions in a powder form for transdermal delivery from a needless syringe
US20020120228A1 (en) 2000-06-08 2002-08-29 Yuh-Fun Maa Powder compositions
TWI289158B (en) 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
GB0020089D0 (en) 2000-08-15 2000-10-04 Smithkline Beecham Biolog Vaccine Composition
KR20030061810A (ko) 2000-09-25 2003-07-22 폴리문 사이언티픽 임무노이비오로기쉐 포르슝 게엠베하 생균 백신과 제조 방법
US20040033239A1 (en) 2001-03-06 2004-02-19 Evans Robert K Adenovirus formulations
EP1370643A1 (en) 2001-03-16 2003-12-17 Oncolytics Biotech, Inc. Method of extracting virus from cell culture
WO2002101412A2 (en) 2001-06-08 2002-12-19 Powderject Vaccines, Inc. Spray freeze-dried compositions
GB0124710D0 (en) 2001-10-15 2001-12-05 Quadrant Healthcare Uk Ltd Therapeutic composition
WO2003043574A2 (en) 2001-11-19 2003-05-30 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
JP4550421B2 (ja) 2001-12-12 2010-09-22 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド ウイルスの保存のための組成物
US20030153065A1 (en) 2002-01-14 2003-08-14 Genvec, Inc. Composition and method for maintaining non-enveloped viral vectors
BR0306925A (pt) 2002-01-18 2004-11-09 Schering Ag Formulações estabilizadas de adenovìrus
EP1494651A4 (en) 2002-04-11 2010-10-13 Medimmune Vaccines Inc PRESERVATION OF BIOACTIVE MATERIALS WITH FREEZZED FOAM
AU2003230908A1 (en) 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
AU2003234090A1 (en) 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
DK1501921T4 (da) 2002-04-30 2012-10-08 Oncolytics Biotech Inc Forbedrede virusrensningsmetoder
DK1556477T3 (en) 2002-11-01 2017-10-23 Glaxosmithkline Biologicals Sa Process for drying
US6752740B2 (en) 2002-11-12 2004-06-22 Jeffery T. Semmes Continuously variable transmission
AU2003297320B8 (en) 2002-12-17 2008-02-21 Medimmune, Llc High pressure spray-dry of bioactive materials
US6931888B2 (en) 2003-02-07 2005-08-23 Ferro Corporation Lyophilization method and apparatus for producing particles
NZ543467A (en) 2003-04-10 2008-07-31 Novartis Vaccines & Diagnostic The severe acute respiratory syndrome coronavirus
WO2005021033A2 (en) 2003-09-02 2005-03-10 Glaxosmithkline Biologicals S.A. Vaccine
EP1692279A4 (en) 2003-11-19 2006-12-27 Merck & Co Inc VIRUS PREPARATIONS CONTAINING A CONSERVATIVE
WO2005058356A2 (en) * 2003-12-17 2005-06-30 Wyeth Methods for porducing storage stable viruses and immunogenic compositions thereof
WO2005066333A1 (en) 2003-12-30 2005-07-21 Aventis Pasteur, Inc. Stabilizing compositions for recombinant viruses
GB0404586D0 (en) 2004-03-01 2004-04-07 Britannia Pharmaceuticals Ltd Improvements in or relating to organic materials
EP1720519A1 (en) 2004-03-04 2006-11-15 Wyeth Lyophilization method to improve excipient crystallization
EP1750760B1 (en) 2004-06-02 2017-06-28 Universal Stabilization Technologies, Inc. Preservation by vaporization
WO2006029467A1 (en) 2004-09-16 2006-03-23 Btf Pty Ltd Rapid freeze drying process
AR050959A1 (es) 2004-09-28 2006-12-06 Alza Corp Estabilizacion de agentes inmunologicamente activos adyuvados con alumbre
US7901921B2 (en) 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
WO2006052813A2 (en) * 2004-11-05 2006-05-18 Wellstat Biologics Corporation Stable and filterable enveloped virus formulations
DE602005009402D1 (de) 2004-12-09 2008-10-09 Precimed Sa Operationsinstrumentenhalter für leichtere sterilisation
US20060141483A1 (en) * 2004-12-23 2006-06-29 Calton Gary J Stabilization of viral compositions
NZ595313A (en) 2005-02-18 2013-03-28 Abraxis Bioscience Llc The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
EP1954308B1 (en) * 2005-09-16 2011-09-07 Merial Ltd. Stabilizers for freeze-dried vaccines
CN1765181A (zh) 2005-10-19 2006-05-03 路兴波 高效抗病毒制剂
DK2007883T3 (da) 2006-04-20 2012-02-06 Wyeth Llc Rensningsfremgangsmåder til isolering af renset vesikulær stomatitis-virus fra cellekultur
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
EP1854478A1 (en) 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation
EP1878791A1 (en) 2006-07-11 2008-01-16 Bia Separations D.O.O. Method for influenza virus purification
US8030020B2 (en) 2006-08-07 2011-10-04 Juridicial Foundation The Chemo-Sero-Therapeutic Research Institute Process for preparing live smallpox vaccine
KR20090060453A (ko) 2006-09-25 2009-06-12 메디뮨 엘엘씨 안정화된 항체 제제 및 그것의 용도
WO2008058035A1 (en) 2006-11-03 2008-05-15 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
AU2007317847B2 (en) * 2006-11-07 2013-10-31 Sanofi Pasteur Biologics, Llc Stabilization of vaccines by lyophilization
NZ577855A (en) 2006-12-27 2012-07-27 Pfizer Prod Inc Vaccination schedule to prevent canine disease
US20080299182A1 (en) 2007-03-01 2008-12-04 Shuyuan Zhang Methods and formulations for topical gene therapy
CA2678721C (en) * 2007-03-12 2018-02-13 Oncolytics Biotech Inc. Reoviruses having modified sequences
GB0705245D0 (en) 2007-03-19 2007-04-25 Stabilitech Ltd Stable biological products
DK2829282T3 (en) * 2007-03-22 2018-01-02 Univ Colorado Regents Process for preparing an immunologically active adjuvant-linked dried vaccine composition
PT2144998T (pt) 2007-04-06 2017-04-07 Takeda Vaccines Inc Métodos e composições para vírus vivos atenuados
AR066649A1 (es) 2007-05-21 2009-09-02 Oncolytics Biotech Inc Reovirus mutantes y metodos de elaboracion y uso de los mismos
EP2197283B1 (en) * 2007-09-25 2013-07-17 Aridis Pharmaceuticals Formulations for preservation of rota virus
EP3424525A1 (en) 2007-10-12 2019-01-09 Massachusetts Institute Of Technology Vaccine nanotechnology
WO2009056651A1 (en) 2007-11-02 2009-05-07 Cytos Biotechnology Ag Angiotensin-carrier formulation
CN104059143A (zh) 2007-11-12 2014-09-24 特罗科隆科学有限公司 用于对流行性感冒进行治疗以及诊断的组合物以及方法
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
JP2011514337A (ja) * 2008-02-25 2011-05-06 ノババックス，インコーポレイテッド 糖ガラス化ウィルス様粒子（ｖｌｐ）
PT2473528E (pt) * 2009-09-03 2015-03-04 Ablynx NV Formulações estáveis de polipéptidos e seus usos
CA2819246C (en) * 2010-12-02 2023-04-25 Oncolytics Biotech Inc. Liquid viral formulations
US9044498B2 (en) 2010-12-02 2015-06-02 Oncolytics Biotech Inc. Lyophilized viral formulations
ES2822199T3 (es) * 2011-04-29 2021-04-29 Oncolytics Biotech Inc Métodos de purificación de virus usando cromatografía por permeación en gel
JP6065096B2 (ja) 2015-12-25 2017-01-25 ダイキン工業株式会社 調湿装置

Also Published As

Publication number Publication date
WO2012075376A2 (en) 2012-06-07
CA2819236A1 (en) 2012-06-07
IL226646B (en) 2018-02-28
DK2646052T3 (en) 2017-07-17
SG190419A1 (en) 2013-06-28
EA201390812A1 (ru) 2013-11-29
KR20140014096A (ko) 2014-02-05
JP2016199591A (ja) 2016-12-01
EP2646052A2 (en) 2013-10-09
US9610352B2 (en) 2017-04-04
US20150224198A1 (en) 2015-08-13
JP2018172443A (ja) 2018-11-08
US20120141528A1 (en) 2012-06-07
JP6433954B2 (ja) 2018-12-05
CN103269716B (zh) 2015-05-27
MX2013006169A (es) 2013-10-28
EP2646052B1 (en) 2017-03-29
KR102023207B1 (ko) 2019-11-25
WO2012075376A3 (en) 2012-08-16
CN103269716A (zh) 2013-08-28
AU2011336410A1 (en) 2013-03-28
AU2011336410B2 (en) 2015-01-22
EP2646052A4 (en) 2014-01-08
TW201233803A (en) 2012-08-16
JP2013544288A (ja) 2013-12-12
JP6034797B2 (ja) 2016-11-30
US9044498B2 (en) 2015-06-02
ES2630012T3 (es) 2017-08-17

Similar Documents

Publication Publication Date Title
MX349294B (es) Formulaciones virales liofilizadas.
WO2012075379A3 (en) Liquid viral formulations
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
CA2817005A1 (en) Rabies glycoprotein virus-like particles (vlps)
PH12018501602A1 (en) Subunit immersion vaccines for fish
IN2014MN01548A (es)
MX349825B (es) Virus atenuados utiles para vacunas.
MX2012008221A (es) Inhibidores de virus flaviviridae.
MX2012008211A (es) Inhibidores de virus flaviviridae.
MX2013001237A (es) Compuestos inhibidores del virus de la hepatitis c.
EA201190327A1 (ru) Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
WO2008156778A3 (en) Influenza m2 protein mutant viruses as live influenza attenuated vaccines
WO2011082388A3 (en) Infectious dna vaccines against chikungunya virus
PH12013502442A1 (en) Inactivated dengue virus vaccine
MX2013010620A (es) Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo.
UA103330C2 (ru) Вакцина против инфекционного бронхита, полученная из ib-qx-подобных штаммов
MX2013003245A (es) Vacuna contra virus de diarrea viral de bovinos.
MX2017008342A (es) Composiciones de vacuna para el virus del dengue y metodos de uso de las mismas.
WO2014008475A3 (en) Compositions and methods related to viral vaccines
MA35303B1 (fr) Vaccin contre la rhinite equine
GB201008123D0 (en) Novel compounds
WO2012003030A3 (en) Methods of identifying & using anti-viral compounds
MX2012002702A (es) Vacuna de herpesvirus bovino.
MX2024003507A (es) Mutantes del virus de la influenza b y usos de los mismos.

Legal Events

Date Code Title Description
FG Grant or registration